Development of a small animal peripheral challenge model of Japanese encephalitis virus using interferon deficient AG129 mice and the SA14-14-2 vaccine virus strain

Vaccine

Volumn 32, Issue 2, 2014, Pages 258-264

  Calvert, Amanda E ^a   Dixon, Kandice L ^a   Delorey, Mark J ^a   Blair, Carol D ^b   Roehrig, John T ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

AG129 mouse model; Flavivirus; Flavivirus pathogenesis; Interferon deficient mice; Japanese encephalitis virus; JEV SA14 14 2 vaccine strain; Viral encephalitis

Indexed keywords

ALPHA INTERFERON RECEPTOR; BETA INTERFERON RECEPTOR; C REACTIVE PROTEIN; CD40 ANTIGEN; CD40 LIGAND; CXCL3 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GAMMA INTERFERON RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12P70; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; JAPANESE ENCEPHALITIS VACCINE; KERATINOCYTE DERIVED CHEMOKINE; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; MONOCYTE CHEMOTACTIC PROTEIN 5; ONCOSTATIN M; RANTES; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BODY TEMPERATURE MEASUREMENT; BRAIN LEVEL; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; EXPERIMENTAL MODEL; INFLAMMATION; JAPANESE ENCEPHALITIS VIRUS; MORBIDITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN; SURVIVAL TIME; THERMOMETER; TISSUE LEVEL; VIRUS ENCEPHALITIS; VIRUS PLAQUE; VIRUS STRAIN; VIRUS TITRATION; VIRUS VIRULENCE;

AG129 MOUSE MODEL; FLAVIVIRUS; FLAVIVIRUS PATHOGENESIS; INTERFERON-DEFICIENT MICE; JAPANESE ENCEPHALITIS VIRUS; JEV SA14-14-2 VACCINE STRAIN; VIRAL ENCEPHALITIS;

ANIMALS; DISEASE MODELS, ANIMAL; ENCEPHALITIS VIRUS, JAPANESE; ENCEPHALITIS, JAPANESE; INTERFERONS; JAPANESE ENCEPHALITIS VACCINES; MICE; VACCINES, ATTENUATED; VIRAL LOAD;

EID: 84890557641     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.11.016     Document Type: Article

References (48)

1. van den Hurk A.F., Ritchie S.A., Mackenzie J.S. Ecology and geographical expansion of Japanese encephalitis virus. Annu Rev Entomol 2009, 54:17-35.
2. Mackenzie J.S., Williams D.T. The zoonotic flaviviruses of southern, south-eastern and eastern Asia, and Australasia: the potential for emergent viruses. Zoonoses Public Health 2009, 56(6-7):338-356.
3. Beasley D.W., Lewthwaite P., Solomon T. Current use and development of vaccines for Japanese encephalitis. Expert Opin Biol Ther 2008, 8(1):95-106.
4. Tauber E., Kollaritsch H., Korinek M., Rendi-Wagner P., Jilma B., Firbas C., et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 2007, 370(9602):1847-1853.
5. Tauber E., Kollaritsch H., von Sonnenburg F., Lademann M., Jilma B., Firbas C., et al. Randomized: double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J Infect Dis 2008, 198(4):493-499.
6. Schuller E., Klade C.S., Wolfl G., Kaltenbock A., Dewasthaly S., Tauber E. Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study. Vaccine 2009, 27(15):2188-2193.
7. Dubischar-Kastner K., Kaltenboeck A., Klingler A., Jilma B., Schuller E. Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine: IXIARO (IC51), in 6 months of follow-up. Vaccine 2010, 28(39):6463-6469.
8. Clark D.C., Brault A.C., Hunsperger E. The contribution of rodent models to the pathological assessment of flaviviral infections of the central nervous system. Arch Virol 2012, 157(8):1423-1440.
9. Spotts D.R., Reich R.M., Kalkhan M.A., Kinney R.M., Roehrig J.T. Resistance to alpha/beta interferons correlates with the epizootic and virulence potential of Venezuelan equine encephalitis viruses and is determined by the 5' noncoding region and glycoproteins. J Virol 1998, 72(12):10286-10291.
10. Johnson A.J., Roehrig J.T. New mouse model for dengue virus vaccine testing. J Virol 1999, 73(1):783-786.
11. Calvert A.E., Huang C.Y., Kinney R.M., Roehrig J.T. Non-structural proteins of dengue 2 virus offer limited protection to interferon-deficient mice after dengue 2 virus challenge. J Gen Virol 2006, 87(Pt 2):339-346.
12. Thibodeaux B.A., Garbino N.C., Liss N.M., Piper J., Blair C.D., Roehrig J.T. A small animal peripheral challenge model of yellow fever using interferon-receptor deficient mice and the 17D-204 vaccine strain. Vaccine 2012, 30(21):3180-3187.
13. Ruppert D., Wand M.P., Carroll R.J. Semiparametric regression 2003, Cambridge University Press, Cambridge, United Kingdom.
14. Huang C.Y., Butrapet S., Pierro D.J., Chang G.J., Hunt A.R., Bhamarapravati N., et al. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J Virol 2000, 74(7):3020-3028.
15. Solomon T., Dung N.M., Kneen R., Gainsborough M., Vaughn D.W., Khanh V.T. Japanese encephalitis. J Neurol Neurosurg Psychiatry 2000, 68(4):405-415.
16. Halstead S.B., Thomas S.J. New vaccines for Japanese encephalitis. Curr Infect Dis Rep 2010, 12(3):174-180.
17. Yu Y.X., Wu P.F., Ao J., Liu L.H., Li H.M. Selection of better immunogenic and highly attenuated live vaccine virus strain of Japanese encephalitis. I. Some biological characteristics of SA14-14-2 mutant. Chin J Microbiol Immunol 1981, 1:77-85.
18. Eckels K.H., Yu Y.X., Dubois D.R., Marchette N.J., Trent D.W., Johnson A.J. Japanese encephalitis virus live-attenuated vaccine: Chinese strain SA14-14-2; adaptation to primary canine kidney cell cultures and preparation of a vaccine for human use. Vaccine 1988, 6(6):513-518.
19. Kumar R., Tripathi P., Rizvi A. Effectiveness of one dose of SA 14-14-2 vaccine against Japanese encephalitis. N Engl J Med 2009, 360(14):1465-1466.
20. Hennessy S., Liu Z., Tsai T.F., Strom B.L., Wan C.M., Liu H.L., et al. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. Lancet 1996, 347(9015):1583-1586.
21. Yu Y.X., Zhang G.M., Guo Y.P., Ao J., Li H.M. Safety of a live-attenuated Japanese encephalitis-virus vaccine (Sa14-14-2) for children. Am J Trop Med Hygiene 1988, 39(2):214-217.
22. Eder S., Dubischar-Kastner K., Firbas C., Jelinek T., Jilma B., Kaltenboeck A., et al. Long term immunity following a booster dose of the inactivated Japanese encephalitis vaccine IXIARO(R): IC51. Vaccine 2011, 29(14):2607-2612.
23. Heinz F.X., Stiasny K. Flaviviruses and flavivirus vaccines. Vaccine 2012, 30(29):4301-4306.
24. Ni H., Chang G.J., Xie H., Trent D.W., Barrett A.D. Molecular basis of attenuation of neurovirulence of wild-type Japanese encephalitis virus strain SA14. J Gen Virol 1995, 76(Pt 2).
25. Arroyo J., Guirakhoo F., Fenner S., Zhang Z.X., Monath T.P., Chambers T.J. Molecular basis for attenuation of neurovirulence of a yellow fever virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J Virol 2001, 75(2):934-942.
26. Chambers T.J., Droll D.A., Jiang X., Wold W.S., Nickells J.A. JE Nakayama/JE SA14-14-2 virus structural region intertypic viruses: biological properties in the mouse model of neuroinvasive disease. Virology 2007, 366(1):51-61.
27. Liang J.J., Liao C.L., Liao J.T., Lee Y.L., Lin Y.L. A Japanese encephalitis virus vaccine candidate strain is attenuated by decreasing its interferon antagonistic ability. Vaccine 2009, 27(21):2746-2754.
28. Lee E., Lobigs M. Mechanism of virulence attenuation of glycosaminoglycan-binding variants of Japanese encephalitis virus and Murray Valley encephalitis virus. J Virol 2002, 76(10):4901-4911.
29. Nitayaphan S., Grant J.A., Chang G.J., Trent D.W. Nucleotide sequence of the virulent SA-14 strain of Japanese encephalitis virus and its attenuated vaccine derivative: SA-14-14-2. Virology 1990, 177(2):541-552.
30. King N.J., Getts D.R., Getts M.T., Rana S., Shrestha B., Kesson A.M. Immunopathology of flavivirus infections. Immunol Cell Biol 2007, 85(1):33-42.
31. Diamond M.S., Roberts T.G., Edgil D., Lu B., Ernst J., Harris E. Modulation of dengue virus infection in human cells by alpha: beta, and gamma interferons. J Virol 2000, 74(11):4957-4966.
32. Li Y., Xu M., Chen L., Zhu J., Ye J., Liu X., et al. Evaluation of murine bone marrow-derived dendritic cells loaded with inactivated virus as a vaccine against Japanese encephalitis virus. Vaccine 2009, 27(43):6004-6010.
33. Cao S., Li Y., Ye J., Yang X., Chen L., Liu X., et al. Japanese encephalitis Virus wild strain infection suppresses dendritic cells maturation and function, and causes the expansion of regulatory T cells. Virol J 2011, 8:39.
34. Sooryanarain H., Sapkal G.N., Gore M.M. Pathogenic and vaccine strains of Japanese encephalitis virus elicit different levels of human macrophage effector functions. Arch Virol 2012, 157(10):1905-1918.
35. Thibodeaux B.A., Garbino N.C., Liss N.M., Piper J., Schlesinger J.J., Blair C.D., et al. A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model. Antiviral Res 2012, 94(1):1-8.
36. Ogata A., Nagashima K., Hall W.W., Ichikawa M., Kimura-Kuroda J., Yasui K. Japanese encephalitis virus neurotropism is dependent on the degree of neuronal maturity. J Virol 1991, 65(2):880-886.
37. Taylor J.L., Schoenherr C., Grossberg S.E. Protection against Japanese encephalitis virus in mice and hamsters by treatment with carboxymethylacridanone: a potent interferon inducer. J Infect Dis 1980, 142(3):394-399.
38. Lin Y.L., Liao C.L., Yeh C.T., Chang C.H., Huang Y.L., Huang Y.Y., et al. A highly attenuated strain of Japanese encephalitis virus induces a protective immune response in mice. Virus Res 1996, 44(1):45-56.
39. Ishag H.Z., Li C., Huang L., Sun M.X., Wang F., Ni B., et al. Griffithsin inhibits Japanese encephalitis virus infection in vitro and in vivo. Arch Virol 2013, 158(2):349-358.
40. 8+ T cells to recovery from infection in a murine model of Japanese encephalitis. J Virol 2011, 85(11):5446-5455.
41. Larena M., Prow N.A., Hall R.A., Petrovsky N., Lobigs M. JE-ADVAX vaccine protection against Japanese encephalitis virus mediated by memory B cells in the absence of CD8(+) T cells and pre-exposure neutralizing antibody. J Virol 2013, 87(8):4395-4402.
42. Klingel K., Schnorr J.J., Sauter M., Szalay G., Kandolf R. Beta2-microglobulin-associated regulation of interferon-gamma and virus-specific immunoglobulin G confer resistance against the development of chronic coxsackievirus myocarditis. Am J Pathol 2003, 162(5):1709-1720.
43. Winter P.M., Dung N.M., Loan H.T., Kneen R., Wills B., Thu le T., et al. Proinflammatory cytokines and chemokines in humans with Japanese encephalitis. J Infect Dis 2004, 190(9):1618-1626.
44. Ravi V., Parida S., Desai A., Chandramuki A., Gourie-Devi M., Grau G.E. Correlation of tumor necrosis factor levels in the serum and cerebrospinal fluid with clinical outcome in Japanese encephalitis patients. J Med Virol 1997, 51(2):132-136.
45. Wang T., Town T., Alexopoulou L., Anderson J.F., Fikrig E., Flavell R.A. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med 2004, 10(12):1366-1373.
46. Daffis S., Samuel M.A., Suthar M.S., Gale M., Diamond M.S. Toll-like receptor 3 has a protective role against West Nile virus infection. J Virol 2008, 82(21):10349-10358.
47. Biswas S.M., Kar S., Singh R., Chakraborty D., Vipat V., Raut C.G., et al. Immunomodulatory cytokines determine the outcome of Japanese encephalitis virus infection in mice. J Med Virol 2010, 82(2):304-310.
48. Zhang J.S., Zhao Q.M., Zuo S.Q., Jia N., Guo X.F. Cytokine and chemokine responses to Japanese encephalitis live attenuated vaccine in a human population. Int J Infect Dis 2012, 16(4):e285-e288.